Skip to main content
. Author manuscript; available in PMC: 2022 May 26.
Published in final edited form as: Mol Cancer Res. 2021 Jan 29;19(5):913–920. doi: 10.1158/1541-7786.MCR-20-0738

Figure 1: Gilteritinib treatment inhibits activation of NPM1-ALK fusion kinase.

Figure 1:

NPM1-ALK expressing SR-786, DEL, SUP-M2, SU-DHL-1, and Ba/F3-FG-NPM1-ALK cells were treated with indicated concentrations of gilteritinib for 24 hours. At the end of the treatment period, cell lysates were made, and Western blot analyses were performed for phospho-NPM1-ALK and total NPM1-ALK proteins. β-actin served as the loading control.